DaVita had a strong Q2 financially, with adjusted operating income growing 6% year-over-year and adjusted earnings per share increasing by 35%. The company is optimistic about integrated kidney care, believing it can improve patient outcomes and reduce healthcare costs. DaVita is increasing its guidance for the full year, excluding the potential impact of a significant fourth COVID surge, with an adjusted operating income range of $1.8 billion to $1.875 billion and free cash flow of $1 billion to $1.2 billion. Adjusted earnings per share are projected to be between $8.80 and $9.40, with an effective tax rate of 24% to 26%. Despite headwinds from COVID and new value-based care arrangements, DaVita remains confident in its future growth and plans to invest in its integrated kidney care business in 2022.